EU Approves First Lyme Vaccine | Toronto News

A breakthrough could be on the horizon: the EU is reviewing a new Lyme disease vaccine developed by Pfizer and Valneva, showing 70% effectiveness in trials. With Lyme now the most common tick-borne illness—and no vaccine available—this could be a game-changer, especially as climate change expands tick habitats. The news sent Valneva’s stock soaring 16%, highlighting global urgency as over 14% of people worldwide have had Lyme at some point. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/b939c6c272eea4ce